Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $32.00

Key Points

• Citigroup raised Ultragenyx Pharmaceutical’s price target to $32 from $31 and maintained a “Buy” rating, implying 123.15% upside from the prior close.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and average price target of $37.26, although several firms recently downgraded the stock or reduced their targets.
• RARE shares traded at $14.34, near their 52-week low, while the company’s latest quarter exceeded expectations with revenue up 28.5% year over year and a smaller-than-expected loss.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) had its target price raised by Citigroup from $31.00 to $32.00 in a report issued on Friday, Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. Citigroup's price target indicates a potential upside of 123.15% from the company's previous close.

RARE has been the subject of several other research reports. Royal Bank Of Canada downgraded shares of Ultragenyx Pharmaceutical from a "moderate buy" rating to a "hold" rating in a research note on Thursday, September 3rd. William Blair cut Ultragenyx Pharmaceutical from an "outperform" rating to a "market perform" rating in a research report on Thursday, September 3rd. Guggenheim dropped their target price on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 4th. Wall Street Zen upgraded shares of Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, JPMorgan Chase & Co. cut shares of Ultragenyx Pharmaceutical from an "overweight" rating to a "neutral" rating and cut their price target for the stock from $80.00 to $36.00 in a report on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $37.26.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE traded down $0.16 during mid-day trading on Friday, reaching $14.34. 2,429,122 shares of the company's stock were exchanged, compared to its average volume of 2,590,477. The business's fifty day simple moving average is $24.26 and its 200-day simple moving average is $24.49. The stock has a market capitalization of $1.41 billion, a PE ratio of -2.46 and a beta of 0.31. Ultragenyx Pharmaceutical has a 52-week low of $12.73 and a 52-week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The firm had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. During the same quarter in the prior year, the firm earned ($1.17) EPS. Ultragenyx Pharmaceutical's revenue for the quarter was up 28.5% on a year-over-year basis. Equities research analysts predict that Ultragenyx Pharmaceutical will post -3.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth $311,000. IFP Advisors Inc increased its stake in shares of Ultragenyx Pharmaceutical by 191.7% during the 2nd quarter. IFP Advisors Inc now owns 2,313 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 1,520 shares in the last quarter. Allworth Financial LP increased its stake in shares of Ultragenyx Pharmaceutical by 130.9% during the 2nd quarter. Allworth Financial LP now owns 4,699 shares of the biopharmaceutical company's stock worth $157,000 after purchasing an additional 2,664 shares in the last quarter. Nykredit A S acquired a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $154,000. Finally, Corient Private Wealth LP lifted its stake in Ultragenyx Pharmaceutical by 7.3% in the 2nd quarter. Corient Private Wealth LP now owns 146,493 shares of the biopharmaceutical company's stock valued at $4,891,000 after buying an additional 9,949 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: FAYUVI’s approval represents Ultragenyx’s second gene-therapy approval and sixth FDA approval overall. The company expects shipments to qualified treatment centers within 30–60 days and will provide patient-access assistance through its UltraCare program. Ultragenyx Announces Approval of FAYUVI
• Positive Sentiment: Clinical data showed a durable treatment effect and a 23.5-point cognitive-score advantage versus a natural-history cohort, supporting the potential for meaningful clinical benefit. Ultragenyx also received a Priority Review Voucher that could have strategic or financial value. FDA approves Ultragenyx gene therapy
• Positive Sentiment: Canaccord Genuity raised its price target from $37 to $39 and maintained a Buy rating, while Cantor Fitzgerald increased its target from $33 to $39 and assigned an Overweight rating. These revisions indicate improved analyst expectations following the approval.
• Positive Sentiment: The stock’s recent advance occurred on above-average volume, while favorable earnings-estimate revisions may support additional near-term momentum. Ultragenyx stock and earnings estimate revisions
• Neutral Sentiment: Ultragenyx set FAYUVI’s price at $3.95 million, creating substantial revenue potential per patient but also making insurance coverage, reimbursement, and treatment-center access critical to the launch.
• Negative Sentiment: FAYUVI carries important safety risks, including elevated liver enzymes, thrombocytopenia, infusion reactions, and a potential malignancy risk. Long-term commercial adoption and safety remain uncertainties.
• Negative Sentiment: A previously reported failed Angelman syndrome trial and a law-firm investigation into potential investor claims remain overhangs. In addition, reported insider activity consisted entirely of sales over the past six months.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company's work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx's marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.